EFFICACY OF CAVERGAL IN PATIENTS WITH CORONARY HEART DISEASE AND METABOLIC SYNDROME
Khidoyatova Mukhlisa Raxmatillaevna*, Inoyatova Feruza Khidoyatovna and Aripov Abdumalik Nigmatovich
Were examined 50 patients aged 45 - 53 years, suffering from stable exertionangina of the II functional class and metabolic syndrome (MS). Patients were randomized into two groups of 25 people. In the main group, cavergal was added to the basic therapy at a dose of 0.9 g / day. The duration of the study was 12 weeks. It was shown that cavergal as part of the complex therapy of coronary heart disease (CHD) in patients with MS contributes to reducing the number of strokes and improves the quality of life of patients. Inclusion of a cavergal in the combined therapy of CHD on the background of MS has a positive effect on lipid and carbohydrate metabolism, significantly reduces the severity of insulin resistance.
Keywords: metabolic syndrome, coronary heart disease, cavergal, insulin resistance, carbohydrate and lipid metabolism.
[Full Text Article]